Related Experiment Video

Updated: Aug 17, 2026

Mouse Model of Oleic Acid-Induced Acute Respiratory Distress Syndrome
04:45

Mouse Model of Oleic Acid-Induced Acute Respiratory Distress Syndrome

Published on: June 2, 2022

Poly(ADP-ribosyl)ation in asthma and other lung diseases

László Virág1

  • 1Department of Medical Chemistry, Research Center for Molecular Medicine, Medical and Health Science Center, University of Debrecen, H-4026 Debrecen, Bem tér 18/B, Hungary. lvirag@dote.hu

Pharmacological Research
|May 25, 2005
PubMed

Insights

Inhibiting poly(ADP-ribosyl)ation, particularly poly(ADP-ribose) polymerase-1 (PARP-1), shows promise as an anti-inflammatory treatment for asthma and other oxidative stress conditions.

Area of Science:

  • Biomedical Science
  • Molecular Biology
  • Immunology

Background:

  • Poly(ADP-ribosyl)ation is implicated in oxidative stress-related pathologies.
  • Emerging evidence suggests poly(ADP-ribose) polymerase-1 (PARP-1) activation plays a role in asthma.
  • PARP inhibition demonstrates anti-inflammatory effects in various disease models.

Purpose of the Study:

  • To discuss the role of poly(ADP-ribosyl)ation in asthma pathogenesis.
  • To review the complex regulatory functions of PARP-1 in inflammatory processes.
  • To explore the potential of PARP inhibition as an anti-inflammatory strategy for respiratory diseases.

Main Methods:

  • Review of existing literature on PARP-1 and inflammation in asthma models.
  • Analysis of data linking PARP-1 activation to inflammatory signal transduction pathways (e.g., NF-kappaB).
  • Examination of PARP-1's role in oxidative stress-induced cellular dysfunction and tissue injury.

Main Results:

  • PARP inhibition and PARP-1 knockout exhibit protective effects in asthma models.
  • These protective effects are attributed to the inhibition of inflammatory signaling and oxidative stress.
  • Poly(ADP-ribosyl)ation influences inflammatory cell migration, cytokine production, and mediator expression in asthma.

Conclusions:

  • PARP-1 plays a complex role in regulating inflammatory responses in asthma.
  • Targeting poly(ADP-ribosyl)ation presents a potential therapeutic avenue for asthma.
  • The review also covers PARP-1's involvement in other oxidative stress-related lung diseases.

More Related Videos

A Method for Generating Pulmonary Neutrophilia Using Aerosolized Lipopolysaccharide08:33

A Method for Generating Pulmonary Neutrophilia Using Aerosolized Lipopolysaccharide

Published on: December 15, 2014

Related Concept Videos

Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms: